PerpEquities

Equity

Is Alnylam Pharmaceuticals, Inc. (ALNY) tradable as a perp? Not right now

Alnylam Pharmaceuticals discovers, develops and commercializes RNAi-based therapies, including approved treatments ONPATTRO, GIVLAARI and OXLUMO, for genetic, cardio-metabolic, hepatic and CNS disorders.

Currently not listed on any perp exchange

ALNY traded as a perpetual on MEXC until October 23, 2026. No venue lists it at the moment; we keep tracking it, and with the next listing this page becomes a full market page again. Until then: fundamentals below and tradable alternatives.

Similar stocks already tradable as perps
CCTCSOFIDOOSENERLENPTCGFS

Price chart

Interactive TradingView chart

TradingView symbol NASDAQ:ALNY

Loads TradingView's third-party widget (about 1 MB) on demand.

Auto: underlying reference priceOpen in TradingView

Company financials

Financials at a glance

Last report Q3 '26 · filed 2026-10-29 · next report 2027-02-11 · Updated 18h ago
All financials →

Valuation & key figures

Market cap
$20.9B
Updated 18h ago
Revenue
$5B
Trailing 12 months
Revenue growth
+46%
Next fiscal year
Profit margin
+54.3%
P/E
7.7
Peer P/E 29.5
P/S
4.2
Peer P/E
29.5
Similar listed perps
Free cash flow
$500.7M
Trailing 12 months
Net income
$2.7B
Trailing 12 months
Revenue estimate
$5.4B
Next fiscal year
Earnings
2027-02-11
Revenue est. $1.5B · Updated 18h ago
Dividend
-
Revenue (TTM)$5.01B+56.2% vs a year agoLast 4 quarters; bars = each quarter
Operating margin (TTM)19.5%+11.3 pp vs a year agoOperating income $978M
Net income (TTM)$2.72B+6,153.3% vs a year agoAfter tax, incl. non-operating gains
Free cash flow (TTM)$501M+126.2% vs a year agoCapex $150M
Diluted EPS (TTM)$19.80+8,150.0% vs a year agoSum of the last 4 quarters
Net cash$2.33B+64.2% vs a year agoCash + short-term investments - debt
  • Last report (2026-10-29): revenue beat by 1.9%, EPS beat by 879.5%Revenue $1.46B vs $1.43B expected (+1.9%); EPS $16.26 vs $1.66 (+879.5%).
  • Revenue growth slowing: 16.7% year on yearQ3 '26 revenue $1.46B, against an average of 99.4% over the four quarters before.
  • Operating margin 19.5% (TTM), +11.3 pp on a year agoOperating income grew 269.3% while revenue grew 56.2%.
  • 14.2% of pre-tax profit is eaten by non-operating lossesPre-tax income $856M vs operating income $978M (TTM). Losses on equity stakes and other one-off items cut net income and EPS - operating income is the cleaner measure of the business.

Revenue, operating income and growth

quarterly

Revenue by business line

latest quarter
LineRevenuey/yShare
Product$1.29B–92.2%
GIVLAARI$89.5M–6.4%
ONPATTRO$19.6M–1.4%
In the full financialsIncome statement, balance sheet and cash flow (12 quarters / 10 years) · margins and cost structure · capital allocation and buybacks · valuation against the 5-year range · analyst estimates · all 196 lines Alnylam Pharmaceuticals, Inc. reported to the SEC

Research data

Analysts, filings and peer context

Estimates

6
DateEPS estimateRevenue estimateGrowthAnalysts
FY 202618.40$5.4B+46%16
FY 20278.95$6.6B+78%17
FY 202811.15$7.8B+110%17
FY 202912.35$8.7B+135%12
FY 203014.37$9.7B+161%7
Q1 20271.67$1.5B+32%6

Company events

6
2027-02-11EarningsActual - / Estimate 1.72-
2026-10-29Earnings · Before market openActual 16.26 / Estimate 1.66Beat
2026-07-30EarningsActual 1.21 / Estimate 1.63Miss
2026-04-30EarningsActual 1.51 / Estimate 0.87Beat
2026-02-12EarningsActual 0.82 / Estimate 1.16Miss
2025-10-30EarningsActual 1.84 / Estimate 0.56Beat

Peer comparison

Similar listed perps
NameMarket capP/SP/EProfit marginVenues
CCTC$20.9B10.031.0+32.3%1SOFI$21B3.427.9+12.1%16DOOSENER$21.1B1.6131.7+1.3%1LEN$21.1B0.716.8+4.1%3PTC$21.2B7.822.0+37.8%1GFS$21.2B3.0107.3+2.8%6ROKU$21.3B3.946.4+9.3%1AFRM$20.3B4.511.4+44.6%2

Analyst track record

How the analysts covering ALNY have done: ratings, price-target accuracy and the measured reaction after their calls.

12 months3 years
Ratings206636
Analysts3444
Buy / hold / sell164 / 42 / 0494 / 141 / 1
Upgrades / downgrades / initiations0 / 4 / 54 / 6 / 13
Price targets hit / missed0 / 185 (0%)10 / 563 (2%)
Avg. return after a rating (TipRanks)-59.6%-50.0%
Best / worst call-26.5% / -72.1%+19.8% / -72.3%

After buy calls on this stock: median 21-day move +0.2% vs S&P 500 -1.2% (n = 511)

Most accurate on this stock

Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.

  1. Kostas BiliourisOppenheimer100% hit rate on this stock · 21 targets measuredBuytarget $320Nov 5, 2026
  2. William PickeringBernstein100% hit rate on this stock · 10 targets measuredHoldno targetOct 30, 2026
  3. Ritu BaralTD Cowen96% hit rate on this stock · 28 targets measuredBuytarget $354Oct 30, 2026

Latest ratings

DateAnalystCallTarget
Nov 6, 2026Olivia BrayerCantor FitzgeraldHoldMaintained$290article ↗
Nov 6, 2026Olivia BrayerCantor FitzgeraldHoldMaintained$290
Nov 5, 2026Tazeen AhmadBank of America SecuritiesBuyMaintained–article ↗
Nov 5, 2026David LebowitzBMO CapitalBuyReiterated$292article ↗
Nov 5, 2026Kostas BiliourisOppenheimerBuyReiterated$320article ↗
Consensus over the last 12 months buy hold sell avg. target month-end close
Monthly buy, hold and sell shares of analyst ratings with the average price target and the month-end close$150$200$250$300$350$400$450$500Dec 25 · Buy 23 · Hold 7 · Sell 0Dec 25Jan 26 · Buy 21 · Hold 5 · Sell 0Feb 26 · Buy 21 · Hold 4 · Sell 0Feb 26Mar 26 · Buy 20 · Hold 5 · Sell 0Apr 26 · Buy 16 · Hold 5 · Sell 0Apr 26May 26 · Buy 19 · Hold 6 · Sell 0Jun 26 · Buy 20 · Hold 5 · Sell 0Jun 26Jul 26 · Buy 21 · Hold 5 · Sell 0Aug 26 · Buy 24 · Hold 4 · Sell 0Aug 26Sep 26 · Buy 24 · Hold 5 · Sell 0Oct 26 · Buy 24 · Hold 8 · Sell 0Oct 26Nov 26 · Buy 24 · Hold 8 · Sell 0Dec 25 · avg. target $491Jan 26 · avg. target $489Feb 26 · avg. target $471Mar 26 · avg. target $456Apr 26 · avg. target $447May 26 · avg. target $434Jun 26 · avg. target $440Jul 26 · avg. target $398Aug 26 · avg. target $380Sep 26 · avg. target $379Oct 26 · avg. target $336Nov 26 · avg. target $336Dec 25 · month-end close $398Jan 26 · month-end close $338Feb 26 · month-end close $333Mar 26 · month-end close $331Apr 26 · month-end close $309May 26 · month-end close $302Jun 26 · month-end close $301Jul 26 · month-end close $206Aug 26 · month-end close $241Sep 26 · month-end close $247Oct 26 · month-end close $165Nov 26 · month-end close $165

Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.

TipRanks data · computed Nov 7, 2026 · 206 ratings